mPATH® Health, a digital health company focused on improving cancer prevention, has secured $3 million in funding to accelerate its mission of enhancing cancer screening and improving health equity. The funding includes a $2 million Small Business Technology Grant from the National Cancer Institute (NCI) and a $1 million equity investment led by Oncology Ventures.
The NCI grant, awarded in July 2024, will support the commercialization and further development of mPATH’s cancer screening program, which has demonstrated significant success in doubling screening rates across diverse populations. This includes addressing disparities in race, ethnicity, income, and literacy level, contributing to mPATH’s goal of making cancer prevention more accessible. The grant will also enable additional clinical testing of the program.
Dr. David Miller, co-founder of mPATH, expressed his excitement: “This $3 million funding will allow us to rapidly expand our reach, increase cancer screenings, and ultimately save lives. It will also help us document the return on investment for health systems and insurers.”
The $1 million equity investment from Oncology Ventures will enable mPATH to grow its platform, developing additional screening and preventive health modules. Oncology Ventures focuses on companies that improve access to cancer care, aiming to reduce costs and enhance outcomes. Founder Ben Freeberg emphasized the importance of early detection, stating, “Every one-month delay in cancer treatment increases mortality by 10%. By improving access to screening, mPATH can significantly enhance cancer care outcomes at scale.”
With a focus on health equity, mPATH Health is committed to transforming cancer prevention through personalized outreach and cutting-edge technology, ensuring better outcomes for all patients, regardless of background. This funding represents a key milestone in the company’s journey to redefine cancer screening and save lives.
